作者
Diogo Mendes, Carlos Alves, Noémia Afonso, Fátima Cardoso, José Luís Passos-Coelho, Luís Costa, Sofia Andrade, Francisco Batel-Marques
发表日期
2015/12
来源
Breast Cancer Research
卷号
17
页码范围
1-14
出版商
BioMed Central
简介
Introduction
This study aimed at evaluating the overall survival (OS) gain associated with human epidermal growth factor receptor 2 (HER2)-directed therapies in patients with metastatic breast cancer (mBC).
Methods
A bibliographic search was conducted in PubMed and Cochrane databases. Only phase III randomized controlled trials (RCTs) including HER2-positive (HER2+) mBC patients were included in this review. OS was defined as time from randomization until the occurrence of death from any cause. Studies have been grouped according to the line of treatment, i.e., first-line or second-line or beyond.
Results
Nineteen RCTs were eligible for inclusion, of which 12 assessed therapies targeting HER2+ mBC in the first-line setting. OS improved from 20.3 months in the first RCT (standard chemotherapy; Slamon et al …
引用总数
201620172018201920202021202220232024212535282127261812